RAB22A and neoplasm: The RAB22A level in tumor tissues and the STING level in serum may predict the response of cancer patients to chemoradiotherapy (Figs. 2i and 3n), and RAB22A renders tumor cells more sensitive to diABZI in mice by secreting more activated STING via R-EVs (Fig. 3j–l).